

# Adam J Schwarz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7057994/publications.pdf>

Version: 2024-02-01

76  
papers

5,402  
citations

94433

37  
h-index

88630

70  
g-index

78  
all docs

78  
docs citations

78  
times ranked

9430  
citing authors

#	ARTICLE	IF	CITATIONS
1	Endogenous dopamine release in the human brain as a pharmacodynamic biomarker: evaluation of the new GPR139 agonist TAK-041 with [ <sup>11</sup> C]PHNO PET. <i>Neuropsychopharmacology</i> , 2022, 47, 1405-1412.	5.4	9
2	The Open-Access European Prevention of Alzheimer's Dementia (EPAD) MRI dataset and processing workflow. <i>NeuroImage: Clinical</i> , 2022, 35, 103106.	2.7	9
3	First-in-Human Assessment of <sup>11</sup> C-LSN3172176, an M1 Muscarinic Acetylcholine Receptor PET Radiotracer. <i>Journal of Nuclear Medicine</i> , 2021, 62, 553-560.	5.0	35
4	The Use, Standardization, and Interpretation of Brain Imaging Data in Clinical Trials of Neurodegenerative Disorders. <i>Neurotherapeutics</i> , 2021, 18, 686-708.	4.4	19
5	Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort. <i>Alzheimer's and Dementia</i> , 2021, 17, 1189-1204.	0.8	44
6	Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2021, 20, 537-547.	10.2	55
7	Differential resting-state patterns across networks are spatially associated with Comt and Trmt2a gene expression patterns in a mouse model of 22q11.2 deletion. <i>NeuroImage</i> , 2021, 243, 118520.	4.2	4
8	The M1/M4 preferring muscarinic agonist xanomeline modulates functional connectivity and NMDAR antagonist-induced changes in the mouse brain. <i>Neuropsychopharmacology</i> , 2021, 46, 1194-1206.	5.4	21
9	Recommendations to Optimize the Use of Volumetric MRI in Huntington's Disease Clinical Trials. <i>Frontiers in Neurology</i> , 2021, 12, 712565.	2.4	5
10	Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 328-337.	3.7	25
11	Tau Subtypes of Alzheimer's Disease Determined in vivo Using Flortaucipir PET Imaging. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 1037-1048.	2.6	22
12	Memory concerns in the early Alzheimer's disease prodrome: Regional association with tau deposition. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 322-331.	2.4	22
13	Antagonism at the NR2B subunit of NMDA receptors induces increased connectivity of the prefrontal and subcortical regions regulating reward behavior. <i>Psychopharmacology</i> , 2018, 235, 1055-1068.	3.1	21
14	Group II metabotropic glutamate receptor agonist prodrugs LY2979165 and LY2140023 attenuate the functional imaging response to ketamine in healthy subjects. <i>Psychopharmacology</i> , 2018, 235, 1875-1886.	3.1	35
15	Pseudoreference Regions for Glial Imaging with <sup>11</sup> C-PBR28: Investigation in 2 Clinical Cohorts. <i>Journal of Nuclear Medicine</i> , 2018, 59, 107-114.	5.0	32
16	The role of fMRI in drug development. <i>Drug Discovery Today</i> , 2018, 23, 333-348.	6.4	49
17	Secondary prevention of Alzheimer's dementia: neuroimaging contributions. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 112.	6.2	46
18	Alzheimer disease brain atrophy subtypes are associated with cognition and rate of decline. <i>Neurology</i> , 2017, 89, 2176-2186.	1.1	115

#	ARTICLE	IF	CITATIONS
19	Fully Automatic MRI-Based Hippocampus Volumetry Using FSL-FIRST: Intra-Scanner Test-Retest Stability, Inter-Field Strength Variability, and Performance as Enrichment Biomarker for Clinical Trials Using Prodromal Target Populations at Risk for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 151-164.	2.6	7
20	Regional profiles of the candidate tau PET ligand <sup>18</sup> F-AV-1451 recapitulate key features of Braak histopathological stages. <i>Brain</i> , 2016, 139, 1539-1550.	7.6	372
21	An acetylcholine alpha7 positive allosteric modulator rescues a schizophrenia-associated brain endophenotype in the 15q13.3 microdeletion, encompassing CHRNA7. <i>European Neuropsychopharmacology</i> , 2016, 26, 1150-1160.	0.7	34
22	Amyloid status imputed from a multimodal classifier including structural MRI distinguishes progressors from nonprogressors in a mild Alzheimer's disease clinical trial cohort. <i>Alzheimer's and Dementia</i> , 2016, 12, 977-986.	0.8	27
23	Enrichment of clinical trials in MCI due to AD using markers of amyloid and neurodegeneration. <i>Neurology</i> , 2016, 87, 1235-1241.	1.1	34
24	Kinetics of the Tau PET Tracer <sup>18</sup> F-AV-1451 (T807) in Subjects with Normal Cognitive Function, Mild Cognitive Impairment, and Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1535-1542.	5.0	84
25	Large-scale functional connectivity networks in the rodent brain. <i>NeuroImage</i> , 2016, 127, 496-509.	4.2	199
26	Ketamine Suppresses the Ventral Striatal Response to Reward Anticipation: A Cross-Species Translational Neuroimaging Study. <i>Neuropsychopharmacology</i> , 2016, 41, 1386-1394.	5.4	28
27	Relating Translational Neuroimaging and Amperometric Endpoints: Utility for Neuropsychiatric Drug Discovery. <i>Current Topics in Behavioral Neurosciences</i> , 2015, 28, 397-421.	1.7	8
28	A Standardized Method for the Construction of Tracer Specific PET and SPECT Rat Brain Templates: Validation and Implementation of a Toolbox. <i>PLoS ONE</i> , 2015, 10, e0122363.	2.5	52
29	Task-Induced Modulation of Intrinsic Functional Connectivity Networks in the Behaving Rat. <i>Journal of Neuroscience</i> , 2015, 35, 658-665.	3.6	18
30	Modulatory effects of ketamine, risperidone and lamotrigine on resting brain perfusion in healthy human subjects. <i>Psychopharmacology</i> , 2015, 232, 4191-4204.	3.1	19
31	Functional connectivity hubs of the mouse brain. <i>NeuroImage</i> , 2015, 115, 281-291.	4.2	161
32	Quantitative imaging biomarkers: A review of statistical methods for technical performance assessment. <i>Statistical Methods in Medical Research</i> , 2015, 24, 27-67.	1.5	272
33	Comparison of 2 techniques of laryngeal tube exchange in a randomized controlled simulation study. <i>American Journal of Emergency Medicine</i> , 2015, 33, 173-176.	1.6	8
34	Increased Cerebral Vascular Reactivity in the Tau Expressing rTg4510 Mouse: Evidence against the Role of Tau Pathology to Impair Vascular Health in Alzheimer's Disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 359-362.	4.3	25
35	Amygdala habituation: A reliable fMRI phenotype. <i>NeuroImage</i> , 2014, 103, 383-390.	4.2	119
36	Dissociable Effects of Antipsychotics on Ketamine-Induced Changes in Regional Oxygenation and Inter-Regional Coherence of Low Frequency Oxygen Fluctuations in the Rat. <i>Neuropsychopharmacology</i> , 2014, 39, 1635-1644.	5.4	23

#	ARTICLE	IF	CITATIONS
37	Distributed BOLD and CBV-weighted resting-state networks in the mouse brain. <i>NeuroImage</i> , 2014, 87, 403-415.	4.2	199
38	CNVs conferring risk of autism or schizophrenia affect cognition in controls. <i>Nature</i> , 2014, 505, 361-366.	27.8	588
39	Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 421.	0.8	77
40	Operationalizing hippocampal volume as an enrichment biomarker for amnesic mild cognitive impairment trials: effect of algorithm, test-retest variability, and cut point on trial cost, duration, and sample size. <i>Neurobiology of Aging</i> , 2014, 35, 808-818.	3.1	37
41	Simultaneous EEG and fMRI Reveals a Causally Connected Subcortical-Cortical Network during Reward Anticipation. <i>Journal of Neuroscience</i> , 2013, 33, 14526-14533.	3.6	80
42	Noninvasive Phosphorus Magnetic Resonance Spectroscopic Imaging Predicts Outcome to First-line Chemotherapy in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma. <i>Academic Radiology</i> , 2013, 20, 1122-1129.	2.5	9
43	Parallel Buprenorphine pHMRI Responses in Conscious Rodents and Healthy Human Subjects. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 345, 41-51.	2.5	40
44	Anti-Correlated Cortical Networks of Intrinsic Connectivity in the Rat Brain. <i>Brain Connectivity</i> , 2013, 3, 503-511.	1.7	55
45	Enriching Amnesic Mild Cognitive Impairment Populations for Clinical Trials: Optimal Combination of Biomarkers to Predict Conversion to Dementia. <i>Journal of Alzheimer's Disease</i> , 2012, 32, 373-385.	2.6	29
46	Decision-making using fMRI in clinical drug development: revisiting NK-1 receptor antagonists for pain. <i>Drug Discovery Today</i> , 2012, 17, 964-973.	6.4	48
47	Modulation of CNS pain circuitry by intravenous and sublingual doses of buprenorphine. <i>NeuroImage</i> , 2012, 59, 3762-3773.	4.2	48
48	Test-retest reliability of evoked BOLD signals from a cognitive-emotive fMRI test battery. <i>NeuroImage</i> , 2012, 60, 1746-1758.	4.2	268
49	Negative edges and soft thresholding in complex network analysis of resting state functional connectivity data. <i>NeuroImage</i> , 2011, 55, 1132-1146.	4.2	208
50	A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development #2: protocol optimization and best practices. <i>Drug Discovery Today</i> , 2011, 16, 671-682.	6.4	25
51	A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development #1: processes and requirements. <i>Drug Discovery Today</i> , 2011, 16, 583-593.	6.4	28
52	Imaging Drugs with and without Clinical Analgesic Efficacy. <i>Neuropsychopharmacology</i> , 2011, 36, 2659-2673.	5.4	64
53	Functional connectivity in the rat brain: a complex network approach. <i>Magnetic Resonance Imaging</i> , 2010, 28, 1200-1209.	1.8	30
54	A Statistical Framework for Optimal Design Matrix Generation With Application to fMRI. <i>IEEE Transactions on Medical Imaging</i> , 2010, 29, 1573-1611.	8.9	2

#	ARTICLE	IF	CITATIONS
55	Robust, unbiased general linear model estimation of phMRI signal amplitude in the presence of variation in the temporal response profile. <i>Journal of Magnetic Resonance Imaging</i> , 2010, 31, 1445-1457.	3.4	9
56	A Neural Switch for Active and Passive Fear. <i>Neuron</i> , 2010, 67, 656-666.	8.1	183
57	Improved characterization of BOLD responses for evoked sensory stimuli. <i>NeuroImage</i> , 2010, 49, 2275-2286.	4.2	19
58	Phosphorus Magnetic Resonance Spectroscopy Predicts Outcome to Chemotherapy In Patients with Diffuse Large B-Cell Lymphoma: A Prospective International Multicenter Analysis of a Pretreatment Metabolic Biomarker of Response. <i>Blood</i> , 2010, 116, 3104-3104.	1.4	0
59	Community structure in networks of functional connectivity: Resolving functional organization in the rat brain with pharmacological MRI. <i>NeuroImage</i> , 2009, 47, 302-311.	4.2	52
60	Drug-anaesthetic interaction in phMRI: the case of the psychotomimetic agent phencyclidine. <i>Magnetic Resonance Imaging</i> , 2008, 26, 999-1006.	1.8	54
61	Pharmacological stimulation of NMDA receptors via co-agonist site suppresses fMRI response to phencyclidine in the rat. <i>Psychopharmacology</i> , 2008, 201, 273-284.	3.1	58
62	Community structure and modularity in networks of correlated brain activity. <i>Magnetic Resonance Imaging</i> , 2008, 26, 914-920.	1.8	78
63	Differential Effects of Antipsychotic and Glutamatergic Agents on the phMRI Response to Phencyclidine. <i>Neuropsychopharmacology</i> , 2008, 33, 1690-1703.	5.4	111
64	In vivo mapping of functional connectivity in neurotransmitter systems using pharmacological MRI. <i>NeuroImage</i> , 2007, 34, 1627-1636.	4.2	112
65	1,2,4-Triazol-3-yl-thiopropyl-tetrahydrobenzazepines: A Series of Potent and Selective Dopamine D <sub>3</sub> Receptor Antagonists. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 5076-5089.	6.4	84
66	Effects of cocaine on blood flow and oxygen metabolism in the rat brain: implications for phMRI. <i>Magnetic Resonance Imaging</i> , 2007, 25, 795-800.	1.8	11
67	A multimodality investigation of cerebral hemodynamics and autoregulation in pharmacological MRI. <i>Magnetic Resonance Imaging</i> , 2007, 25, 826-833.	1.8	76
68	Pharmacological modulation of functional connectivity: the correlation structure underlying the phMRI response to d-amphetamine modified by selective dopamine D3 receptor antagonist SB277011A. <i>Magnetic Resonance Imaging</i> , 2007, 25, 811-820.	1.8	69
69	Study-level wavelet cluster analysis and data-driven signal models in pharmacological MRI. <i>Journal of Neuroscience Methods</i> , 2007, 159, 346-360.	2.5	34
70	A stereotaxic MRI template set for the rat brain with tissue class distribution maps and co-registered anatomical atlas: Application to pharmacological MRI. <i>NeuroImage</i> , 2006, 32, 538-550.	4.2	292
71	Region-Specific Effects of Nicotine on Brain Activity: A Pharmacological MRI Study in the Drug-Naïve Rat. <i>Neuropsychopharmacology</i> , 2006, 31, 1690-1703.	5.4	74
72	Functional magnetic resonance mapping of intracerebroventricular infusion of a neuroactive peptide in the anaesthetised rat. <i>Journal of Neuroscience Methods</i> , 2005, 142, 115-124.	2.5	20

#	ARTICLE	IF	CITATIONS
73	Wavelet-based cluster analysis: data-driven grouping of voxel time courses with application to perfusion-weighted and pharmacological MRI of the rat brain. <i>NeuroImage</i> , 2005, 24, 281-295.	4.2	38
74	Selective dopamine D3 receptor antagonist SB-277011-A potentiates phMRI response to acute amphetamine challenge in the rat brain. <i>Synapse</i> , 2004, 54, 1-10.	1.2	73
75	Functional MRI using intravascular contrast agents: detrending of the relative cerebrovascular (rCBV) time course. <i>Magnetic Resonance Imaging</i> , 2003, 21, 1191-1200.	1.8	49
76	Considerations regarding voxel brightness in volumetric displays utilizing two-step excitation processes. <i>Optical Engineering</i> , 1993, 32, 2818.	1.0	10